Sun Wenwen, Dou Jinxia, Zhang Lin, Qiao Likui, Shen Na, Gao Wenyuan
Wenwen Sun, Centre Lab, Tianjin Key Laboratory for Modern Drug Delivery & High-Efficiency, School of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, China. Tianjin 4th Centre Hospital, Tianjin 300140, China.
Jinxia Dou, Centre Lab, Tianjin Key Laboratory for Modern Drug Delivery & High-Efficiency, School of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, China. Tianjin 4th Centre Hospital, Tianjin 300140, China.
Pak J Med Sci. 2017 Mar-Apr;33(2):425-429. doi: 10.12669/pjms.332.11687.
To detect the expression of CD133, E-cadherin and WWOX in colorectal cancer, analyze the correlations and pathological significance of the biomarkers.
Two hundred and ten patients with colorectal cancer treated surgically between January 2007 and December 2015 were analyzed retrospectively. All patients had pathologic specimens and integrated clinical data. Pathologic specimens were retrieved for immunohistochemical examination of the expressions of CD133, WWOX and E-cadherin. The clinical data of these patients including gender, age, tumor location, tumor size, tumor differentiation, invasion depth, hepatic metastases, lymphatic metastasis, UICC stage and recurrence of tumor were retrieved to investigate their demographics and clinical characteristics.
In 210 specimens of colorectal cancer, the positive expression rate of CD133, E-cadherin and WWOX was 61.9%, 40.5% and 41.9%, respectively. The expression of CD133, E-cadherin and WWOX was significantly correlated with lymphatic metastasis, hepatic metastases and UICC stage (p<0.05). The expression of CD133 was negatively correlated with WWOX and E-cadherin (p<0.05), and the expression of WWOX was positively correlated with E-cadherin in specimens (p<0.05).
A detection of CD133, E-cadherin and WWOX can facilitate physicians in predicting the progression and prognosis of colorectal cancer.
检测CD133、E-钙黏蛋白和WWOX在结直肠癌中的表达，分析这些生物标志物的相关性及病理意义。
回顾性分析2007年1月至2015年12月间接受手术治疗的210例结直肠癌患者。所有患者均有病理标本及完整的临床资料。获取病理标本进行CD133、WWOX和E-钙黏蛋白表达的免疫组化检测。收集这些患者的临床资料，包括性别、年龄、肿瘤部位、肿瘤大小、肿瘤分化程度、浸润深度、肝转移、淋巴转移、国际抗癌联盟（UICC）分期及肿瘤复发情况，以研究其人口统计学特征和临床特点。
在210例结直肠癌标本中，CD133、E-钙黏蛋白和WWOX的阳性表达率分别为61.9%、40.5%和41.9%。CD133、E-钙黏蛋白和WWOX的表达与淋巴转移、肝转移及UICC分期显著相关（p<0.05）。CD133的表达与WWOX和E-钙黏蛋白呈负相关（p<0.05），且在标本中WWOX的表达与E-钙黏蛋白呈正相关（p<0.05）。
检测CD133、E-钙黏蛋白和WWOX有助于医生预测结直肠癌的进展和预后。
